Fungal infections in children with cancer: A prospective, multicenter surveillance study

Pediatric Infectious Disease Journal

Volumn 25, Issue 7, 2006, Pages 634-639

  Castagnola, Elio ^a   Cesaro, Simone ^b,c   Giacchino, Mareva ^q   Livadiotti, Susanna ^d   Tucci, Fabio ^e   Zanazzo, Giulio ^f   Caselli, Desirè ^g   Caviglia, Ilaria ^a   Parodi, Stefano ^a   Rondelli, Roberto ^h   Cornelli, Pier Emilo ⁱ   Mura, Rossella ^j   Santoro, Nicola ^k   Russo, Giovanna ^l   De Santis, Raffaella ^m   Buffardi, Salvatore ⁿ   Viscoli, Claudio ^o   Haupt, Riccardo ^a   Rossi, Mario R ^p  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Hospital S Anna   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^g Di Cristina Hospital   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ OSPEDALI RIUNITI   (Italy)

^j Osp Regionale per le Microcitemie   (Italy)

^k UNIVERSITY OF BARI   (Italy)

^l Laboratorio di Catania   (Italy)

^m Unit of Pediatrics   (Italy)

ⁿ Ospedale Pausillipon   (Italy)

^o UNIVERSITY OF GENOA   (Italy)

^p SAN GERARDO HOSPITAL   (Italy)

^q G Gaslini Children's Hospital ^*

more..

Author keywords

Bone marrow transplant; Deep tissue mycoses; Fungemia; Leukemia; Solid tumor

Indexed keywords

ADOLESCENT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; FEMALE; FUNGEMIA; HUMAN; ITALY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LONGITUDINAL STUDIES; MALE; MYCOSES; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 33745698978     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000220256.69385.2e     Document Type: Article

References (56)

1. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33:23-32.
2. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis. 1992;11:99-109.
3. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore). 1998;77:246-254.
4. Groll AH, Kurz M, Schneider W, et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses. 1999;42:431-442.
5. Abbasi S, Shenep JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: A 34-year experience. Clin Infect Dis. 1999;29:1210-1219.
6. Hovi L, Saarinen-Pihkala UM, Vettenranta K, Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: Single center experience of 10 years. Bone Marrow Transplant. 2000;26:999-1004.
7. Krupova Y, Sejnova D, Dzatkova J, et al. Prospective study on fungemia in children with cancer: Analysis of 35 cases and comparison with 130 fungemias in adults. Support Care Cancer. 2000;8:427-430.
8. Ridola V, Chachaty E, Raimondo G, et al. Candida infections in children treated with conventional chemotherapy for solid tumors (transplant recipients excluded): The Institut Gustave Roussy Pediatrics Department experience. Pediatr Blood Cancer. 2004;42:332-337.
9. Mullen CA, Abd El-Baki H, Samir H, Tarrand JJ, Rolston KV. Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients. Support Care Cancer. 2003;11:321-325.
10. Rosen GP, Neilsen K, Glenn S, Abelson J, Deville J, Moore TB. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol. 2005;27:135-140.
11. Dvorak CC, Steinbach WJ, Brown JM, Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2005;36:621-629.
12. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplant: An international consensus. Clin Infect Dis. 2002;34:7-14.
13. Measures of variations. In: Armitage P, Berry G, eds. Statistical Methods in Medical Research, 2nd ed. Oxford: Blackwell Scientific Publications; 1987:32-41.
14. Viscoli C, Castagnola E, Giacchino M, et al. Bloodstream infections in children with cancer: A multicentre surveillance study of the Italian Association of Paediatric Haematology and Oncology. Supportive Therapy Group-Infectious Diseases Section. Eur J Cancer. 1999;35:770-774.
15. Brugnara C. Reference values in infancy and childhood. In: Nathan DG, Orkin SH, Ginsburg D, Look AT, eds. Nathan and Oski's Hematology of Infancy and Childhood. Philadelphia: WB Saunders Co; 2003:1835-1864.
16. Pession A, Rondelli R, Haupt R, et al. Sistema di rilevazione dei casi di tumore maligno in età pediatrica in Italia su base ospedaliera (the Italian Hospital Based Registry of Pediatric Cancer). Ital J Pediatr. 2000;26:333-341.
17. Sulahian A, Touratier S, Ribaud P. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med. 2003;349:2366-2367.
18. Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin- tazobactam. Clin Infect Dis. 2004;38:913-916.
19. Adam O, Auperin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis. 2004;38:917-920.
20. Maertens J, Theunissen K, Verhoef G, Van Eldere J. False-positive Aspergillus galactomannan antigen test results. Clin Infect Dis. 2004;39:289-290.
21. Subira M, Martino R, Rovira M, Vazquez L, Serrano D, De La Camara R. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Ann Hematol. 2003;82:80-82.
22. Castagnola E, Caviglia I, Pistorio A, et al. Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: A 13-year experience at a single Italian institution. Eur J Cancer. 2005;41:1439-1445.
23. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis. 2001;32:358-366.
24. Segal BH, Bow EJ, Menichetti F. Fungal infections in nontransplant patients with hematologic malignancies. Infect Dis Clin North Am. 2002;16:935-964.
25. Ostrosky-Zeichner L, Rex JH, Bennett J, Kullberg BJ. Deeply invasive candidiasis. Infect Dis Clin North Am. 2002;16:821-835.
26. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood. 2002;100:4358-4366.
27. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459-1466.
28. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28:1071-1079.
29. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781-803.
30. Pagano L, Girmenia C, Mele L, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica. 2001;86:862-870.
31. Pagano L, Mele L, Fianchi L, et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica. 2002;87:535-541.
32. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantations: Comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995;86:3979-3986.
33. Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994;84:2221-2228.
34. Mackall CL, Stein D, Fleisher TA, et al. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood. 2000;96:754-762.
35. Ohmagari N, Raad II, Hachem R, Kontoyiannis DP. Invasive aspergillosis in patients with solid tumors. Cancer. 2004;101:2300-2302.
36. Romani L. Immunity to fungal infections. Nat Rev Immunol. 2004;4:1-23.
37. Haupt R, Romanengo M, Fears T, Viscoli C, Castagnola E. Incidence of septicaemias and invasive mycoses in children undergoing treatment for solid tumours: A 12-year experience at a single Italian institution. Eur J Cancer. 2001;37:2413-2419.
38. Grigull L, Beier R, Schrauder A, et al. Invasive fungal infections are responsible for one-fifth of the infectious deaths in children with ALL. Mycoses. 2003;46:441-446.
39. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103-1110.
40. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
41. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39:1563-1571.
42. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patient using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15:139-147.
43. Archibald S, Park J, Geyer JR, Hawkins DS. Computed tomography in the evaluation of febrile neutropenic pediatric oncology patients. Pediatr Infect Dis J. 2001;20:5-10.
44. Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol. 1997;99:580-588.
45. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37:634-643.
46. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3597 patients. J Clin Oncol. 2003;21:4615-4626.
47. Kanda Y, Yamamoto R, Chizuka A, et al. Prophylaxis action of oral fluconazole against fungal infection in neutropenic patients. Cancer. 2000;89:1611-1625.
48. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 2001;135:412-422.
49. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764-771.
50. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225-234.
51. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391-1402.
52. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med. 2000;108:282-289.
53. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin B. Cancer.2003;97:1025-1032.
54. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98:292-299.
55. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797-802.
56. Viscoli C. Combination therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:803-805.